Sivgin, S. Et Al. 2013. The oral iron chelator deferasirox might improve survival in allogeneic hematopoietic cell transplant (alloHSCT) recipients with transfusional iron overload. TRANSFUSION AND APHERESIS SCIENCE , vol.49, no.2 , 295-301.

Sivgin, S., Baldane, S., AKYOL, G., Keklik, M., KAYNAR, L., Kurnaz, F., ... Pala, C.(2013). The oral iron chelator deferasirox might improve survival in allogeneic hematopoietic cell transplant (alloHSCT) recipients with transfusional iron overload. TRANSFUSION AND APHERESIS SCIENCE , vol.49, no.2, 295-301.

Sivgin, Serdar Et Al. "The oral iron chelator deferasirox might improve survival in allogeneic hematopoietic cell transplant (alloHSCT) recipients with transfusional iron overload," TRANSFUSION AND APHERESIS SCIENCE , vol.49, no.2, 295-301, 2013

Sivgin, Serdar Et Al. "The oral iron chelator deferasirox might improve survival in allogeneic hematopoietic cell transplant (alloHSCT) recipients with transfusional iron overload." TRANSFUSION AND APHERESIS SCIENCE , vol.49, no.2, pp.295-301, 2013

Sivgin, S. Et Al. (2013) . "The oral iron chelator deferasirox might improve survival in allogeneic hematopoietic cell transplant (alloHSCT) recipients with transfusional iron overload." TRANSFUSION AND APHERESIS SCIENCE , vol.49, no.2, pp.295-301.

@article{article, author={Serdar ŞIVGIN Et Al. }, title={The oral iron chelator deferasirox might improve survival in allogeneic hematopoietic cell transplant (alloHSCT) recipients with transfusional iron overload}, journal={TRANSFUSION AND APHERESIS SCIENCE}, year=2013, pages={295-301} }